Rainbow Childrens Medicare / Q2-FY26

RAINBOW Q2 FY26 earnings call.

A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

Watch2025-10-15Back to RAINBOW

Revenue

₹445 Cr

verified against source

Revenue YoY

6.5%

reported change

EBITDA

₹149 Cr

latest reported figure

Source

screener in

record provenance

Actual signal trajectory

Where this quarter sits.

source records only
EBITDA (₹ Cr)PositiveWatchNegative
2 actual records
Actual quarterly EBITDA (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q2 FY26: 149 · Watch source sentiment · 2025-10-15Q2 FY26Q3 FY26: 147 · Watch source sentiment · 2026-02-03Q3 FY26149147
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Quarter read

What the record says.

Rainbow Children's Medicare reported a muted Q2 FY26 with revenue of ₹445 crore (+6.5% YoY) and EBITDA of ₹149 crore (+1% YoY) at a 33.5% margin, impacted by lower seasonal illness incidence compressing pediatric and PICU volumes. Occupancy dropped to 52% versus typical 64-66% in Q2, representing an 8-10pp shortfall attributed to absent seasonal respiratory illnesses and early festive timing. The PAT stood at ₹75.6 crore (+4% YoY). Key positives include new hospital Rajahmundry commissioning, Prashanthi (Guwahati) and Pratika (Warangal) integration progressing with revenue uptick expected from December, and Electronic City (Bangalore) awaiting regulatory approvals. Management maintained 20% CAGR growth guidance over the next 2-3 years driven by capacity additions and new facility ramp-up. The H2 trajectory hinges on seasonal normalization and successful commissioning of Bangalore spoke hospitals. Key risks include persistent medical visa restrictions affecting international revenues, Gurugram construction delays due to Delhi NCR pollution controls, and the structurally low-margin nature of the Madhukar Trust operations (15-16% EBITDA ceiling).

Colored figures show movement against the previous available record.

Guidance to track

  • Management targets 20% revenue CAGR driven by 780-bed capacity expansion ramp-up, new facility maturation (Rajahmundry, Electronic City, Hennur), and acquisition integration (Guwahati, Warangal).
  • Remaining capex for H2 includes Electronic City and Hennur completions plus Gurugram project payments. Three-year capex budget (FY27-29) of ₹600 crore for Kimbatur, Pune, and NCR expansion.
  • 90-bed facility in Bangalore Electronic City is fully constructed and awaiting government approvals for clinical commencement. Hennur (60 beds) expected to commence by January 2026.
  • Rajahmundry: 15-18 months; Hennur: 12 months; Electronic City: 15 months. Previous hospitals (Sarjapur, Anand Nagar) achieved break-even on schedule despite Q2 seasonality impact.

Risks flagged

  • Medical visa restrictions for Bangladesh and other key markets continue to constrain international patient flow. Monthly revenue tracking at ₹3 crore versus historical ₹1 crore/month. Africa markets showing some recovery but full normalization uncertain.
  • Government-mandated construction halts in Delhi NCR due to dangerously high pollution levels have stalled work on both Gurugram sector 44 and sector 56 hospitals, potentially impacting FY27 completion timeline.
  • Analyst questioned EBITDA margin trajectory for Madhukar Trust. Management acknowledged 15-16% is the ceiling even in best scenarios due to free bed allocations for children, with ₹23-24 crore principal outstanding and restructured repayment schedule.
  • Analyst questioned whether geographic diversification would reduce seasonality impact. Management acknowledged South India (Hyderabad, Bangalore, Andhra Pradesh) behaves as one seasonal cluster, while North/Northeast follow different patterns but won't provide meaningful diversification for 2-3 years.

Key quotes

  • We expect normalisation in upcoming quarters. The underlying business fundamentals remain strong with the continued growth in speciality services, disciplined cost management and steady progress in operational efficiency.
  • I think we moving forward we should do about 20% growth that's what next two years is which we aim at because we have done all the expansions we've added the plenty of beds in the growing business areas and as long as we stabilize our matured units to kind of 8-10% of growth rest of them grow at about 25% to confirm related we do 20% growth.
  • Because most of the adult hospitals are surgically driven we are medical hospital. So in medical hospital the cost of implants and the other is much lower and hence you see higher gross margins.

Research modules

Go one layer deeper.